High Net Worth Advisory Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

High Net Worth Advisory Group’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,000	Closed	-$111K	–	211
2022 Q4	$111K	Buy	3,000 +1,000	+50%	+$35.5K	0.04%	236
2022 Q3	$56K	Buy	2,000 +500	+33%	+$12.5K	0.02%	307
2022 Q2	$29K	Buy	1,500 +1,000	+200%	+$11.9K	0.01%	397
2022 Q1	$6K	Buy	+500	New	+$11.3K	﹤0.01%	575

Other funds holding AMLX

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

High Net Worth Advisory Group's AMLX Position: Q1 2023 in Review

High Net Worth Advisory Group sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2023, closing a stake of 3,000 shares — an estimated $111K sold.

High Net Worth Advisory Group first reported a position in AMLX in Q1 2022 and held it in 4 quarters. The position peaked at $111K in Q4 2022. 147 funds tracked by Wall St. Rank hold AMLX as of Q1 2023.

High Net Worth Advisory Group reported no remaining Amylyx Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
High Net Worth Advisory Group sold 3,000 Amylyx Pharmaceuticals shares in Q1 2023, an estimated $111K.
High Net Worth Advisory Group first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 4 quarters.
High Net Worth Advisory Group's Amylyx Pharmaceuticals position peaked at $111K in Q4 2022.
147 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2023.

Based on High Net Worth Advisory Group's 13F filing for Q1 2023, filed 20 Apr 2023.